Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature [0.03%]
异基因供者造血细胞移植后使用减量环磷酰胺治疗原发性骨髓纤维化患者的预后良好：挑战与文献回顾
Irene García-Cadenas,Sara Redondo,Albert Esquirol et al.
Irene García-Cadenas et al.
Engraftment and nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (allo-HCT) depend greatly on the transplantation platform in patients with myelofibrosis (MF). We report outcomes of 14 consecutive MF patients w...
Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma [0.03%]
大B细胞淋巴瘤和多发性骨髓瘤CAR-T治疗后的复发及耐药机制和治疗方法
Kai Rejeski,Michael D Jain,Eric L Smith
Kai Rejeski
Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority of patients attain long-term disease remission. The underl...
Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms [0.03%]
优化供体嵌合阈值以进行异基因干细胞移植后髓系肿瘤可测量残留病的下一代测序监测
Christian J Puzo,Christopher A Tormey,Henry M Rinder et al.
Christian J Puzo et al.
Next-generation sequencing (NGS) is used to monitor genetically measurable residual disease (gMRD) following allogeneic stem cell transplantation (aSCT). It is unknown whether an upper limit of chimerism exists such that gMRD NGS testing ca...
Impact of Chronic Graft-versus-Host Disease on Patient Employment, Income, and Informal Caregiver Burden: Findings From the Living With Chronic GVHD Patient Survey [0.03%]
慢性移植物抗宿主病对患者就业、收入和非专业护理负担的影响：来自慢性GVHD生存者调查的结果
Jingbo Yu,Nandita Khera,James Turnbull et al.
Jingbo Yu et al.
The development of chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) results in impaired physical function and quality of life. However, limited data exist regarding the employment and ...
Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant [0.03%]
难治性霍奇金淋巴瘤患者高强度化疗及自体干细胞移植的影响因素和长期生存分析
Saad Akhtar,M Shahzad Rauf,Tusneem Ahmed M Elhassan et al.
Saad Akhtar et al.
Patients with primary refractory Hodgkin lymphoma (ref-HL) can still be salvaged with high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT). Outcomes of patients with ref-HL is poorer than those with relapsed HL, ...
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma [0.03%]
克服复发/难治性弥漫大B细胞淋巴瘤患者进行嵌合抗原受体T细胞治疗转诊障碍的难关
Marc S Hoffmann,Bradley D Hunter,Patrick W Cobb et al.
Marc S Hoffmann et al.
Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma. Although outcomes to frontline therapy are encouraging, patients who are refractory to or in relapse after first-line therapy experience inferior o...
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy [0.03%]
用于治疗CAR-T细胞疗法后难治性细胞因子释放综合征或免疫效应细胞相关神经毒性的安尼克拉注射液
Nicolas Gazeau,Emily C Liang,Qian Vicky Wu et al.
Nicolas Gazeau et al.
Chimeric antigen receptor-engineered (CAR)-T cell therapy remains limited by significant toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The optimal management of sev...
FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study [0.03%]
FLT3内部串联重复等位基因比率和NPM1突变不影响allo-HSCT后FLT3-ITD急性髓系白血病患者预后的临床研究
Cuiyan Zhou,Fengmei Zheng,Lanping Xu et al.
Cuiyan Zhou et al.
FLT3-ITD mutation has consistently been correlated with poor outcomes in patients with acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays a major role in curing blood diseases. Whether allo-HS...
Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation [0.03%]
减强度预处理异基因造血干细胞移植后早期移植肾损伤的临床特征分析
Juliana Vergara-Cadavid,P Connor Johnson,Haesook T Kim et al.
Juliana Vergara-Cadavid et al.
Allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative therapy for patients with hematologic malignancies but is associated with acute kidney injury (AKI). To date, few studies have examined risk factors for AKI ...
A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease [0.03%]
评估急性移植物抗宿主病患者报告的结果的试验
Sagar S Patel,Sanghee Hong,Lisa Rybicki et al.
Sagar S Patel et al.
Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Acute GVHD is associated with severe physical and psychosocial symptoms. We sought to evaluate the...